Report: Sales of drugs approved this year could hit $18.7B in 5 years

11/14/2013 | American City Business Journals

A report from EP Vantage forecasts that the combined sales of 34 drugs expected to be approved in the U.S. this year could reach a record $18.7 billion by 2018, up 14% from the estimated five-year revenue of 43 drugs cleared last year. If approved before the year ends, Gilead Sciences' hepatitis C drug sofosbuvir will be the top revenue-generating drug with expected sales of $3 billion by 2018, followed by Biogen Idec's Tecfidera with $2.9 billion in potential sales.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI